Thomas Shrader

BTIG | Healthcare

Thomas Shrader is an analyst from BTIG specializing in the Healthcare sector. Ranked #683 out of 4535 analysts, they have issued 37 stock ratings with a success rate of 74.45% and an average return of 38.71%.

Thomas Shrader has a well-established track record, with 37 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 74.45% and an average return of 38.71%, underscoring their expertise and ability to identify winning opportunities for investors.

#683

Out of 4535

37

Total Ratings

+74.45%

Success Rate

+38.71%

Average Return

Recent Ratings Analysis

DNLI

Feb 06, 2026

Target

$32.00

Current

$21.08

Performance

0.00%

Thomas Shrader rated DNLI as Buy on Feb 06, 2026, setting a price target of 32. Shares have remained stable near 21.08, leaving the 32 target still in play.

IRD

Jan 28, 2026

Target

$7.00

Current

$3.01

Performance

11.48%

On Jan 28, 2026, IRD was given a Buy rating by Thomas Shrader, with a target price of 7. The stock rallied 11.48% after the rating, narrowing the gap to the target of 7 and validating the bullish stance.

ABOS

Jan 27, 2026

Target

$7.00

Current

$2.40

Performance

-11.76%

ABOS received a Buy rating from Thomas Shrader on Jan 27, 2026, aiming for 7. The rating hasn’t played out as hoped, with the stock trading 11.76% below expectations.

NVAX

Jan 20, 2026

Target

$19.00

Current

$8.25

Performance

0.61%

On Jan 20, 2026, Thomas Shrader published a Buy outlook on NVAX, with a target of 19. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 8.25.

NRXP

Jan 15, 2026

Target

$25.00

Current

$1.91

Performance

-11.16%

Thomas Shrader on Jan 15, 2026 assigned NRXP a Buy rating, with a price target of 25. The call has struggled to gain traction, with shares losing 11.16%.

DRUG

Jan 07, 2026

Target

$147.00

Current

$75.97

Performance

-20.86%

On Jan 07, 2026, Thomas Shrader reaffirmed DRUG with a Buy rating, targeting 147. Shares slid 20.86% despite the recommendation, highlighting downside risks.

IVVD

Dec 23, 2025

Target

$10.00

Current

$1.59

Performance

-43.21%

IVVD was rated Buy by Thomas Shrader on Dec 23, 2025, with a price objective of 10. This case shows how bullish projections can fail, with the stock now below 1.59.

BHVN

Nov 18, 2025

Target

$16.00

Current

$11.60

Performance

22.75%

On Nov 18, 2025, Thomas Shrader initiated coverage on BHVN with a Buy rating and target of 16. The stock’s climb of 22.75% since the call highlights the foresight in the rating.

ANRO

Nov 17, 2025

Target

$27.00

Current

$15.22

Performance

10.29%

Thomas Shrader issued a Buy recommendation for ANRO on Nov 17, 2025, price target set at 27. Investors following the Buy call captured upside momentum, with shares now at 15.22.

COYA

Nov 13, 2025

Target

$16.00

Current

$4.84

Performance

-18.79%

On Nov 13, 2025, COYA was evaluated by Thomas Shrader, who gave a Buy rating and target of 16. Investors saw limited payoff as shares fell short of the 16 target.

PCVX

Nov 10, 2025

Target

$85.00

Current

$56.15

Performance

30.82%

Thomas Shrader rated PCVX as Buy on Nov 10, 2025, setting a price target of 85. The call has proven timely, with shares rising 30.82% toward the price target of 85.

ALDX

Nov 10, 2025

Target

$9.00

Current

$5.53

Performance

7.80%

On Nov 10, 2025, ALDX was given a Buy rating by Thomas Shrader, with a target price of 9. The stock rallied 7.80% after the rating, narrowing the gap to the target of 9 and validating the bullish stance.

STOK

Nov 05, 2025

Target

$39.00

Current

$32.40

Performance

41.98%

STOK received a Buy rating from Thomas Shrader on Nov 05, 2025, aiming for 39. Momentum has favored the Buy call, with shares climbing from 32.4 to 32.4, rewarding those who trusted the recommendation.

ACIU

Nov 04, 2025

Target

$8.00

Current

$3.14

Performance

-4.85%

On Nov 04, 2025, Thomas Shrader published a Buy outlook on ACIU, with a target of 8. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 3.14.

ARCT

Oct 22, 2025

Target

$23.00

Current

$7.57

Performance

-34.40%

Thomas Shrader on Oct 22, 2025 assigned ARCT a Buy rating, with a price target of 23. The call has struggled to gain traction, with shares losing 34.40%.

ALEC

Oct 22, 2025

Target

$0.00

Current

$1.96

Performance

21.74%

On Oct 22, 2025, Thomas Shrader reaffirmed ALEC with a Neutral rating, targeting null. Market strength beyond 1.96 went further than the conservative outlook suggested.

GANX

Oct 15, 2025

Target

$9.00

Current

$1.75

Performance

-6.42%

GANX was rated Buy by Thomas Shrader on Oct 15, 2025, with a price objective of 9. This case shows how bullish projections can fail, with the stock now below 1.75.

CMPS

Oct 13, 2025

Target

$14.00

Current

$6.19

Performance

-1.59%

On Oct 13, 2025, Thomas Shrader initiated coverage on CMPS with a Buy rating and target of 14. Neutral price movement of -1.59% leaves room for interpretation.

HROW

Sep 29, 2025

Target

$63.00

Current

$47.32

Performance

-2.23%

Thomas Shrader issued a Buy recommendation for HROW on Sep 29, 2025, price target set at 63. The target of 63 remains in play, though confirmation will depend on future moves.

VRNA

Jul 10, 2025

Target

$0.00

Current

$106.91

Performance

1.96%

On Jul 10, 2025, VRNA was evaluated by Thomas Shrader, who gave a Neutral rating and target of null. Hold sentiment was validated by subdued trading with no breakout beyond 106.91.

INMB

Jul 01, 2025

Target

$0.00

Current

$1.51

Performance

-27.75%

Thomas Shrader rated INMB as Neutral on Jul 01, 2025, setting a price target of null. The cautious Hold call aligned with subsequent weakness, as shares slipped 27.75%.

OVID

Mar 24, 2025

Target

$4.00

Current

$1.60

Performance

260.12%

On Mar 24, 2025, OVID was given a Buy rating by Thomas Shrader, with a target price of 4. The stock rallied 260.12% after the rating, narrowing the gap to the target of 4 and validating the bullish stance.

Frequency Asked Questions

Who is Thomas Shrader?

Thomas Shrader is an analyst from BTIG specializing in the Healthcare sector.

What is Thomas Shrader's success rate?

Thomas Shrader currently has a success rate of +74.45%.

How many ratings has Thomas Shrader issued?

Thomas Shrader has issued 37 stock ratings so far.

What is the average return of Thomas Shrader's calls?

Their stock ratings have generated an average return of +38.71%.

What is Thomas Shrader's ranking?

Thomas Shrader is ranked #683 out of 4535 analysts.

What types of ratings does Thomas Shrader give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Thomas Shrader?

You can follow Thomas Shrader by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Thomas Shrader?

Their latest rating was a Buy on DNLI issued on 2026-02-06.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep